drugset / Trial / NCT00288236

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

NCT00288236

Phase 3 Completed 368 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary: Effect on HbA1c over 48 weeks in insulin-treated patients with type 2 diabetes Secondary: Effect on glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides - Safety, tolerability

Timeline

Start
2006-01
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rimonabant Small molecule 20 mg